Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05037760




Registration number
NCT05037760
Ethics application status
Date submitted
23/08/2021
Date registered
8/09/2021
Date last updated
17/03/2022

Titles & IDs
Public title
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
Scientific title
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis
Secondary ID [1] 0 0
KER050-MF-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelofibrosis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - KER-050 monotherapy
Treatment: Drugs - KER-050 in combination with ruxolitinib

Experimental: Arm 1a - Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) monotherapy

Experimental: Arm 1b - Dose Escalation KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)

Experimental: Arm 2a - Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) monotherapy

Experimental: Arm 2b - Dose Expansion KER-050 (SC, solution for injection, every 4 weeks) in combination with standard of care ruxolitinib (oral, tablet, twice daily)


Treatment: Drugs: KER-050 monotherapy
KER-050 administered (SC) for up to 13 cycles

Treatment: Drugs: KER-050 in combination with ruxolitinib
KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of adverse events (Safety and Tolerability)
Timepoint [1] 0 0
64 Weeks
Secondary outcome [1] 0 0
Subgroup of transfusion-independent participants
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
Subgroup of participants with anemia requiring red blood cell (RBC) transfusions
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
Proportion of participants with decrease in spleen volume of =35% from baseline as measured by computed tomography (CT) (excluding participants status post splenectomy or splenic irradiation)
Timepoint [3] 0 0
At Week 24 and at Week 52
Secondary outcome [4] 0 0
Proportion of participants with improvement in the Myelofibrosis Symptom Assessment Form Total Symptom Score (MF-SAF-TSS) of =50% from baseline
Timepoint [4] 0 0
At Week 24 and at Week 52
Secondary outcome [5] 0 0
Proportion of participants with progression to AML (bone marrow blasts >20%)
Timepoint [5] 0 0
At Week 24 and at Week 52
Secondary outcome [6] 0 0
Proportion of participants with progression to accelerated MF (bone marrow blasts =10%)
Timepoint [6] 0 0
At Week 24 and at Week 52

Eligibility
Key inclusion criteria
Key

* Male or female =18 years of age, at the time of signing informed consent.
* Diagnosis of PMF, post-PV MF, or post-ET MF according to the 2017 World Health Organization criteria.

Arm-specific criteria:

Arm 1A:

* Previously treated with JAK inhibitor(s) or Participant is ineligible for JAK inhibitor(s)
* Anemia, defined as hemoglobin =10 g/dL during screening, or receiving RBC transfusions

Arm 2A:

* Previously treated with JAK inhibitor(s) or Participant is ineligible for JAK inhibitor(s)
* Anemia, defined as hemoglobin =10 g/dL during screening, or receiving RBC transfusions

Arm-specific criteria for 1B and 2B:

* Has been receiving ruxolitinib for =8 weeks prior to C1D1 and on a stable dose for =4 weeks prior to C1D1.
* Anemia, defined as hemoglobin =10 g/dL during screening, or receiving RBC transfusions

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Presence of the following cardiac conditions:

1. New York Heart Association Class 3 or 4 heart failure
2. QTcF >500 msec on the screening or C1D1 electrocardiogram (ECG)
3. Uncontrolled clinically significant arrhythmia (participants with rate-controlled atrial fibrillation are not excluded)
4. Acute myocardial infarction or unstable angina pectoris <6 months prior to C1D1
* History of stroke, deep venous thrombosis, or arterial embolism within 6 months prior to C1D1.
* Any malignancy other than PMF, post-ET MF, or post-PV MF that has not been in remission and/or has required systemic therapy including radiation, chemotherapy, hormonal therapy, or surgery, within 1 year prior to C1D1. In-situ cancers, squamous cell, and basal cell carcinomas which have been fully excised, and monoclonal gammopathy of unclear significance are allowed at the discretion of the Investigator.
* History of solid organ or hematological transplantation.
* Presence of uncontrolled hypertension, defined as systolic blood pressure =150 mm Hg or diastolic blood pressure =100 mm Hg despite adequate treatment.
* Diagnosis of hemolytic anemia, active bleeding, hemoglobinopathies, or congenital disorders as a cause of the participant's anemia.
* CTCAE Grade =2 bleeding events within the 3 months prior to C1D1.
* Bone marrow blast percentage >2%. Participants with blast % between 2-5% are allowed if at least 2 bone marrows >6 months apart demonstrate stability of blast percentage, these participants must be reviewed with the Medical Monitor prior to study entry.
* Prior treatment with luspatercept, sotatercept, or other commercially available or investigational TGF-ß inhibitors (all Arms)
* Treatment within 28 days prior to C1D1 with:

1. Erythropoiesis stimulating agent (ESA)
2. Granulocyte colony-stimulating factor (G-CSF)
3. Granulocyte-macrophage colony-stimulating factor (GM-CSF)
4. Thrombopoietin agonists (TPO)
5. Immunomodulator imide drugs (IMiDs; e.g., thalidomide, pomalidomide, lenalidomide)
6. Interferon

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
110
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
The Tweed Hospital - Tweed Heads
Recruitment hospital [2] 0 0
Flinders Medical Centre - Woodville South
Recruitment hospital [3] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [4] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [5] 0 0
Ballarat Oncology & Hematology Service - Wendouree
Recruitment postcode(s) [1] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [2] 0 0
5042 - Woodville South
Recruitment postcode(s) [3] 0 0
3355 - Fitzroy
Recruitment postcode(s) [4] 0 0
3050 - Melbourne
Recruitment postcode(s) [5] 0 0
3355 - Wendouree

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Keros Therapeutics, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
IQVIA Biotech
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.
Trial website
https://clinicaltrials.gov/study/NCT05037760
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Rachael Ryzman
Address 0 0
Country 0 0
Phone 0 0
603-548-3907
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05037760